# US 2026/0226092 A1 · Cocrystals of cortexolone 17-propionate and methods for their preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226092 A1
- Document ID: US20260226092A1
- Status: Published application
- Kind: A1
- Application number: 19/147,899
- Filed: 2024-02-05
- Published: 2026-08-06
- Earliest claimed: 2023-07-02
- Assignees: Farmabios S.P.A.
- Applicants: Farmabios S.p.A.
- Inventors: Mauro GABOARDI; Mario DI GIACOMO; Nicolas TESSON; Lydia CÁRDENAS ROMAÑA,; Montserrat TRILLA CASTANO
- Web page: https://patentgrep.com/patent/US20260226092A1

## CPC

- C07J 5/0053: {not substituted in position 16}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- C07C 39/07: containing only methyl groups, e.g. cresols, xylenols
- C07C 39/08: Dihydroxy benzenes; Alkylated derivatives thereof
- C07C 65/10: Salicylic acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Cocrystals of cortexolone 17α-propionate with some coformers are provided, as well as methods for their preparation.

## Claims

### Claim 1

A cocrystal of cortexolone 17α-propionate with a coformer.

### Claim 2 (depends on 1)

The cocrystal according to claim 1, wherein said coformer is a substituted aromatic compound.

### Claim 3 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with salicylic acid in a 2:1 molar ratio in crystalline form B, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 5.4; 13.7; 14.1; 14.4; 14.7; 16.2; 22.6±0.2° 2θ or as reported in FIG. 1 and/or a DSC thermogram as reported in FIG. 2 and/or a proton NMR spectrum as reported in FIG. 3.

### Claim 4 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with resorcinol in a 1:1 molar ratio in crystalline form D, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 10.6; 12.1; 14.6; 14.8; 16.0; 19.7; 21.3±0.2° 2θ or as reported in FIG. 4 and/or a melting point at about 109° C. and a DSC thermogram as reported in FIG. 5 and/or a proton NMR spectrum as reported in FIG. 6.

### Claim 5 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with m-cresol in a 1:1 molar ratio in crystalline form F, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 7.2; 7.5; 9.7; 11.1; 12.4; 14.4; 15.0; 15.1; 16.5; 17.0; 18.3; 20.0; 21.9; 22.3±0.2° 2θ or as reported in FIG. 7 and/or a melting point at about 119° C. and a DSC thermogram as reported in FIG. 8 and/or a proton NMR spectrum as reported in FIG. 9.

### Claim 6 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with m-cresol in a 1:1 molar ratio in crystalline form G, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 7.0; 7.3; 9.5; 12.7; 14.5; 14.7; 15.2; 16.5; 16.6; 17.2; 18.3; 19.9; 21.8±0.2° 2θ or as reported in FIG. 10 and/or a melting point at about 119° C. and a DSC thermogram as reported in FIG. 11 and/or a proton NMR spectrum as reported in FIG. 12.

### Claim 7 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with 3,4-xylenol in a 1:1 molar ratio in crystalline form H, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 8.9; 9.3; 10.3; 12.4; 14.7; 15.1; 16.0; 16.3; 17.7; 19.2; 21.4; 25.1±0.2° 2θ or as reported in FIG. 13 and/or a melting point at about 95° C. and a DSC thermogram as reported in FIG. 14 and/or a proton NMR spectrum as reported in FIG. 15.

### Claim 8 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with o-cresol in a 1:1 molar ratio in crystalline form I, characterized in that the XRPD spectrum has the following characteristic peaks at approximately 8.3; 9.8; 9.9; 11.0; 14.0; 15.2; 15.9; 16.7; 17.6; 17.9; 18.2; 22.1; 23.3; 25.3±0.2° 2θ or as reported in FIG. 16, and/or a melting point at about 79° C. and a DSC thermogram as reported in FIG. 17 and/or a proton NMR spectrum as reported in FIG. 18.

### Claim 9 (depends on 1)

The cocrystal according to claim 1, wherein said cocrystal is cortexolone 17α-propionate with resorcinol in a 1:1 molar ratio in crystalline form J, characterized by the fact that the XRPD spectrum has the following characteristic peaks at approximately 9.0; 9.7; 11.0; 14.4; 14.7; 15.6; 15.9; 16.7; 18.1; 18.2; 18.8; 20.5; 22.2; 22.7; 23.5; 24.8±0.2° 2θ or as reported in FIG. 19 and/or a melting point at about 123° C. and a DSC thermogram as reported in FIG. 20 and/or a proton NMR spectrum as reported in FIG. 21.

### Claim 10

A pharmaceutical composition comprising a cocrystal of cortexolone 17α-propionate and at least a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein said cocrystal is in crystalline form G or in crystalline form J.

### Claim 12 (depends on 2)

The cocrystal according to claim 2, wherein said substituted aromatic compound is selected from a group consisting of salicylic acid, resorcinol, m-cresol, o-cresol, and 3.4-xylenol.
